Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
If approved, Wegovy would become the first oral formulation of a GLP-1 indicated for chronic weight management.
read more
The drugmaker plans to eliminate 516 positions at its facilities in Lawrenceville, New Jersey, as part of a broad restructuring plan.
read more
The new site will support clinical packaging for oral solid dose and capsule-based dry powder inhaler drugs.
read more
The acquisition expands France-based Roquette’s U.S. footprint and adds to the company’s formulation capabilities and drug delivery research and development.
read more
Sanofi announced the closing of the sale of a 50% controlling stake of Opella to U.S. private equity firm Clayton, Dubilier & Rice.
read more
Pfizer has expanded its “cost realignment program” to save an additional $1.2 billion, adding an R&D reorganization to the plan.
read more
The deal will help Merck KGaA to sharpen its focus on rare tumors, as well as strengthen its presence in the U.S.
read more
The agency placed a hold on a phase 1b study of Vyne’s BET inhibitor following an observation of testicular toxicity in dogs from a non-clinical study.
read more
Roche has joined a host of drugmakers who have announced similar initiatives amid concerns about the impact of possible tariffs on imported pharma goods.
read more
The drugmaker says it filed for U.S. approval of semaglutide 25 mg for overweight and obesity earlier this year.
read more
Orforglipron is the first oral GLP-1, taken without food and water restrictions, to successfully complete a phase 3 trial.
read more
The new space enhances the company’s consumer health production capabilities, adding eight new product packaging lines and automated systems in logistics.
read more
The decision comes after a single participant in one of the dose-optimization studies experienced a potential drug-induced liver injury.
read more
Merck will gain non-exclusive global rights to Cyprumed’s oral peptide delivery platform for an undisclosed number of targets.
read more
The five-year investment was promised with the goal of “ensuring all key Novartis medicines for U.S. patients will be made in the United States.”
read more